APA (7th ed.) Citation

KL, M., T, W., TD, D., RD, T., & KA, K. (2025). Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma. Radiation oncology (London, England), 20(1), 132. https://doi.org/10.1186/s13014-025-02691-y

Chicago Style (17th ed.) Citation

KL, McCarty, Watt T, Dan TD, Timmerman RD, and Kumar KA. "Use of PULSAR (personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy) as Consolidation with Immune Checkpoint Inhibition in the Treatment of Pediatric Metastatic Melanoma." Radiation Oncology (London, England) 20, no. 1 (2025): 132. https://doi.org/10.1186/s13014-025-02691-y.

MLA (9th ed.) Citation

KL, McCarty, et al. "Use of PULSAR (personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy) as Consolidation with Immune Checkpoint Inhibition in the Treatment of Pediatric Metastatic Melanoma." Radiation Oncology (London, England), vol. 20, no. 1, 2025, p. 132, https://doi.org/10.1186/s13014-025-02691-y.